One of the leaders in volume daily for penny stocks, Advanced Cell Technology, Inc. (OTC: ACTC), a regenerative medicine working with stem cells, looks forward to conducting Phase I/II clinical trial for Stargardt’s Macular Dystrophy (SMD) after the Wills Eye Institute in Philadelphia received institutional review board (IRB) approval. SMD is a form of juvenile macular degeneration that ACTC is focused on curing by using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.
The IRB at Wills Eye Institute had approved the participation of the institution as a site for ACTC’s clinical trial for dry age-related macular degeneration (dry AMD) earlier this year.
The Phase I/II trial for SMD looks to determine the safety and tolerability of the hESC-derived RPE cells following sub-retinal transplantation into patients with SMD.
ShareFEB
